• 011-26907444
  • raghava@iiitd.ac.in

Browse result page of AntiTbPdb

The total number entries retrieved from this search are 434
IDNameSequenceN-Terminal ModificationC-Terminal ModificationChemical ModificationLinear/CyclicLengthChiralityNatureSourceOriginSpeciesStrainInhibition ConcentrationIn vitro/ In vivoCell LineIntracellular InhibitionCytotoxicityAnimal ModelEffective Dose in model organismImmune ResponceMechanism of ActionTargetCombination TherapyOther ActivitiesYear of PublicationPubmed ID/ Patent No.
antitb_1892Trichoderin BPXXXVVXXAddition of MDA (2-methyl decanoic acid)Addition of AMAE (2-[(20-aminopropyl) methylamino] ethanol)Addition of AHMOD at residue 2 (2-amino-6-hydroxy-4-methyl-8-oxodecanoic acid) and AIB (a-aminoisobutyric acid) at 3,4,7, and 8Cyclic8DNANaturalIsolated from Trichoderma species 05FI48Mycobacterium tuberculosisMycobacterium tuberculosis H37RVMIC = 0.63 μg/mlIn vitroNATratment with this concentration inhibit 100% bacterial growthNANA NANANALipid bilayerNANA201020483615
antitb_1893Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2447 smTIC50 = 15.8 ± 4.5 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1894Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2447 smTIC90 = 34.6 ± 22.4 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1895Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smTIC50 = 11.0 ± 4.1 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1896Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smTIC90 = 65.8 ± 19.13 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1897Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smDIC50 = 15.2± 2.9 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1898Human lactoferricin 1-11GRRRRSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smDIC90 = 37.9 ± 15.9 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1899Human lactoferricin 1-11GKKKKSVQWCAFreeFreeNoneLinear11LCationicNaturalDerived from human lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1900Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2447 smTIC50 = 14.2 ± 1.5 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1901Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2447 smTIC90 = 18.9 ± 4.0 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1902Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smTIC50 = 8.0 ± 1.5 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1903Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smTIC90 = 22.8 ± 9.1 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1904Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smDIC50 = 12.4± 0.3 μMIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1905Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium avium 2-151 smDIC90 = 21.5± 4.0 μMIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1906Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14DCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1907Bovine lactoferricin 17-30FKCRRWQWRMKKLGFreeFreeNoneLinear14DCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1908Bovine lactoferricin 17-30 all KFKCKKWQWKMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1909Bovine lactoferricin 17-30 all KFKCKKWQWKMKKLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1910Bovine lactoferricin 17-30 all RFRCRRWQWRMRRLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 50% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1911Bovine lactoferricin 17-30 all RFRCRRWQWRMRRLGFreeFreeNoneLinear14LCationicNaturalDerived from bovine lactoferricin proteinMycobacterium aviumMycobacterium aviumMycobacterium avium 2447 smTIn vitroNATratment with this concentration inhibit 90% bacterial growthNANA NANANALipid bilayerNANA201424709266
antitb_1915Laterosporulin 10ACVNQCPDAIDRFIVKDKGCHGVEKKYYKQVYVACMNGQHLYCRTEWGGPCQLFreeFreeDisulphide bond between residues 2-43, 6-35 and 20-51 Cyclic53DCationicNaturalDerived from Brevibacillus species SKDU10Mycobacterium smegmatisMycobacterium smegmatis MC2 155MIC = 45 μMIn vitro and ex vivoRAW 264.7 murine macrophageNANo cytotoxicity upto 40 μM/ml concentrationNA NANANACell wall pore formation0.00625 μM of rifampicin with 0.25 μM of peptide, a fourfold reduction in MIC of rifampicin against H37 RVAntibacterial against Staphylococcus aureus MTCC 1430, Bacillus subtilis MTCC 121, Pseudomonas aeruginosa MTCC 1934, Vibrio cholerae MTCC 3904, Escherichia coli MTCC 1610201627267959
antitb_1949YD-1APKGVQGPNGFreeAmidationNoneLinear10LNANaturalDerived from Bacillus amyloliquefaciens CBSYD1Mycobacterium smegmatisMycobacterium smegmatis ATCC 9341MIC = 8 μg/mlIn vitroNANANANA NANANACell wall pore formationNAAntibacterial against gram negative such as Alcaligenes faecalis ATCC 1004, Salmonella Typhimurium KCTC 1925 etc and gram positive bacteria such as Enterococcus faecalis ATCC 29212, Micrococcus luteus ATCC 9341, Staphylococcus aureus KCTC 1928201728050849
antitb_1950NDBP-5IFSAIAGLLSNLLFreeFreeNoneLinear13LCationicNaturalDerived from scorpion hadrurus gertschiMycobacterium abscessus Mycobacterium abscessus subsp. Massiliene GO01MIC = 100 μMIn vitroHuman erythrocyteNANo cytotoxicityBALB/c mice 2mg/kgIFN-y productionNANANANA201728275372
antitb_1951NDBP-5IFSAIAGLLSNLLFreeFreeNoneLinear13LCationicNaturalDerived from scorpion hadrurus gertschiMycobacterium abscessusMycobacterium abscessus subsp. Massiliene GO06MIC = 100 μMIn vitroHuman erythrocyteNANo cytotoxicityBALB/c mice 2mg/kgIFN-y productionNANANANA201728275372
antitb_1952NDBP-5IFSAIAGLLSNLLFreeFreeNoneLinear13LCationicNaturalDerived from scorpion hadrurus gertschiMycobacterium abscessusMycobacterium abscessus subsp. Massiliene GO08MIC = 100 μMIn vitroHuman erythrocyteNANo cytotoxicityBALB/c mice 2mg/kgIFN-y productionNANANANA201728275372
antitb_1966HIDFS1GFGCPFNARRCHRHCRSIRRRAGYCAGRLRLTCTCVRFreeFreeNoneLinear37LCationicNaturalDerived from Haemaphysalis longicornisMycobacterium bovisMycobacterium bovisMIC50 = 0.2 μMIn vitroA549, 293 T, K562 and THP1 cellsNANo cytotoxicity at 20 μMNA NANANANANAAntiibacterial against Bacillus pumilus, Micrococcus luteus, Pseudomonas aeruginosa, Escherichia coli201728446822
antitb_1967HIDFS2GFGCPLNQGACHRHCRSIRRRGGYCSGIIKQTCYFreeFreeNoneLinear34LCationicNaturalDerived from Haemaphysalis longicornisMycobacterium bovisMycobacterium bovisMIC50 = 0.5μMIn vitroA549, 293 T, K562 and THP1 cellsNANo cytotoxicity at 20 μMNA NANANANANAAntiibacterial against Bacillus pumilus, Micrococcus luteus, Pseudomonas aeruginosa, Escherichia coli201728446822
antitb_1968HIDFS1GFGCPFNARRCHRHCRSIRRRAGYCAGRLRLTCTCVRFreeFreeNoneLinear37LCationicNaturalDerived from Haemaphysalis longicornisMycobacterium bovisMycobacterium bovisMIC50 = 0.5 μMIn vitroA549, 293 T, K562 and THP1 cellsNANo cytotoxicity at 20 μMNA NANANANANAAntiibacterial against Bacillus pumilus, Micrococcus luteus, Pseudomonas aeruginosa, Escherichia coli201728446822
antitb_1969HIDFS2GFGCPLNQGACHRHCRSIRRRGGYCSGIIKQTCYFreeFreeNoneLinear34LCationicNaturalDerived from Haemaphysalis longicornisMycobacterium bovisMycobacterium bovisMIC50 = 0.5μMIn vitroA549, 293 T, K562 and THP1 cellsNANo cytotoxicity at 20 μMNA NANANANANAAntiibacterial against Bacillus pumilus, Micrococcus luteus, Pseudomonas aeruginosa, Escherichia coli201728446822
antitb_1970CM-II protein, Sarcotoxin IAGWLKKIGKKIERVGQHTRDATIQGLGIAQQAANVAATARGFreeAmidationNoneLinear40LCationicNaturalNIH-Sape-4, an Embryonic Cell Line of Sarcophaga peregrinaMycobacterium smegmatisMycobacterium smegmatis ATCC607>100 μg/mlIn vitroNoneNoneNANA NoneNANAcell wall (lipid bilayer)NAStaphylococcus aureus FDA209P, Staphylococcus smith, Micrococcus luteus FDA16, Micrococcus luteus IF03333, Micrococcus luteus PC11001, Bacillus subtilis NRRI B-558, Bacillus subtilis PC1219, Corynebacterium bouis 1810, Corynebacterium michiganense, Xantbmonas oryzae, Pseudomonas lachrymans, Escherichia coli NIHJ, Shigella sonnei JS11746, Proteus vulgaris OX1919883182836
antitb_1971SapecinATCDLLSGTGINHSACAAHCLLRGNRGGYCNGKAVCVCRNFreeFreeNoneLinear40LCationicNaturalNIH-Sape-4, an Embryonic Cell Line of Sarcophaga peregrinaMycobacterium smegmatisMycobacterium smegmatis ATCC60778 μg/mlIn vitroNoneNoneNANA NoneNANAcell wall (lipid bilayer)NAStaphylococcus aureus FDA209P, Staphylococcus smith, Micrococcus luteus FDA16, Micrococcus luteus IF03333, Micrococcus luteus PC11001, Bacillus subtilis NRRI B-558, Bacillus subtilis PC1219, Corynebacterium bouis 1810, Corynebacterium michiganense, Xantbmonas oryzae, Pseudomonas lachrymans, Escherichia coli NIHJ, Shigella sonnei JS11746, Proteus vulgaris OX1919883182836
antitb_1972GranulysinRLSPEYYDLARAHLRDEEKSCPCLAQEGPQGDLLTKTQELGRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPLFreeFreeNoneLinear123MixCationicNaturalHomo sapiensMycobacterium tuberculosisMycobacterium tuberculosis90% KillingIn vivoCD8+ TNANANA NANAAltering Membrane Permeabilitycell wall (lipid bilayer)Perforin (2000 U/ml)+granulysin (25 µM)Cryptococcus neoformans, Candida albicans, Leishmania major, S. typhimurium, L. monocytogenes, E. coli, and Staphylococcus aureus19889756476
antitb_1973GranulysinRLSPEYYDLARAHLRDEEKSCPCLAQEGPQGDLLTKTQELGRDYRTCLTIVQKLKKMVDKPTQRSVSNAATRVCRTGRSRWRDVCRNFMRRYQSRVTQGLVAGETAQQICEDLRLCIPSTGPLFreeFreeNoneLinear123MixCationicNaturalHomo sapiensMycobacterium tuberculosisMycobacterium tuberculosis10-15% KillingIn vivoCD8+ TNANANA NANAAltering Membrane Permeabilitycell wall (lipid bilayer)NACryptococcus neoformans, Candida albicans, Leishmania major, S. typhimurium, L. monocytogenes, E. coli, and Staphylococcus aureus19889756476
antitb_1989Ds-defensinVPAESEAAHLRVRRGFGCPLNQGACHNHCRSIRRRGGYCSGIIKQTCTCYRNFreeFreeNoneLinear52LNANaturalDermacentor silvarumMycobacterium bovisMycobacterium bovis (carbenicillin-resistant strain)MIC= 20 µMIn vitroNANANANA NANABacterial lycisCell wallNAFour Gram-positive bacteria, namely, Staphylococcus aureus (CMCC26003), Bacillus pumilus (CMCC63202), Micrococcus luteus (CMCC63202), and Mycobacterium bovis (carbenicillin-resistant strain); and three Gram-negative bacteria, namely, Salmonella typhimurium (CVCC542), Pseudomonas aeruginosa (CVCC2000), and Escherichia coli (CMCC44103),201525588982